Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/59033
Title:
Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer.
Authors:
Hirsch, Fred R; Dziadziuszko, Rafal; Thatcher, Nick; Mann, Helen; Watkins, Claire; Parums, Dinah V; Speake, Georgina; Holloway, Brian; Bunn, Paul A; Franklin, Wilbur A
Abstract:
BACKGROUND: The ISEL (Iressa Survival Evaluation in Lung Cancer) clinical trial evaluated the efficacy of gefitinib versus placebo in pretreated nonsmall-cell lung cancer patients. Two different antibodies, scoring systems, and cutoff points of epidermal growth factor receptor (EGFR) protein expression were compared to predict response and survival of enrolled patients. METHODS: EGFR expression was assessed in tumor samples by immunohistochemistry using the Dako EGFR pharmDx kit (scoring percent of tumor cells with positive staining) and Zymed monoclonal antibody clone 31G7 (scoring staining index derived from proportion of positive cells times staining intensity). RESULTS: Data for EGFR expression were available for 379 patients for Dako and 357 patients for Zymed antibody (22% and 21%, respectively, of trial population). Objective response rates in gefitinib-treated EGFR-positive patients defined with various cutpoints with Dako antibody varied between 8% and 12%, and with Zymed antibody between 10% and 13%. Lower cutoff points with Dako antibody provided the best discrimination between EGFR-positive and EGFR-negative patients for survival hazard ratios comparing gefitinib to placebo, with a significant treatment/cutoff point interaction for 10% cutoff point (P = .049). A similar but less apparent trend was noted for Zymed antibody, although the discrimination between hazard ratios was not significant for any cutoff point analyzed. CONCLUSIONS: Assessment with the Dako PharmDx kit and percentage of cells with positive staining may provide more accurate prediction of differential effect on survival with gefitinib than assessment with Zymed antibody and staining index. Using higher cutpoints to define positivity does not improve test discrimination.
Affiliation:
Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA. Fred.Hirsch@UCHSC.edu
Citation:
Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. 2008, 112 (5):1114-21 Cancer
Journal:
Cancer
Issue Date:
1-Mar-2008
URI:
http://hdl.handle.net/10541/59033
DOI:
10.1002/cncr.23282
PubMed ID:
18219661
Type:
Article
Language:
en
ISSN:
0008-543X
Appears in Collections:
All Christie Publications ; Medical Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorHirsch, Fred R-
dc.contributor.authorDziadziuszko, Rafal-
dc.contributor.authorThatcher, Nick-
dc.contributor.authorMann, Helen-
dc.contributor.authorWatkins, Claire-
dc.contributor.authorParums, Dinah V-
dc.contributor.authorSpeake, Georgina-
dc.contributor.authorHolloway, Brian-
dc.contributor.authorBunn, Paul A-
dc.contributor.authorFranklin, Wilbur A-
dc.date.accessioned2009-04-02T15:51:31Z-
dc.date.available2009-04-02T15:51:31Z-
dc.date.issued2008-03-01-
dc.identifier.citationEpidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. 2008, 112 (5):1114-21 Canceren
dc.identifier.issn0008-543X-
dc.identifier.pmid18219661-
dc.identifier.doi10.1002/cncr.23282-
dc.identifier.urihttp://hdl.handle.net/10541/59033-
dc.description.abstractBACKGROUND: The ISEL (Iressa Survival Evaluation in Lung Cancer) clinical trial evaluated the efficacy of gefitinib versus placebo in pretreated nonsmall-cell lung cancer patients. Two different antibodies, scoring systems, and cutoff points of epidermal growth factor receptor (EGFR) protein expression were compared to predict response and survival of enrolled patients. METHODS: EGFR expression was assessed in tumor samples by immunohistochemistry using the Dako EGFR pharmDx kit (scoring percent of tumor cells with positive staining) and Zymed monoclonal antibody clone 31G7 (scoring staining index derived from proportion of positive cells times staining intensity). RESULTS: Data for EGFR expression were available for 379 patients for Dako and 357 patients for Zymed antibody (22% and 21%, respectively, of trial population). Objective response rates in gefitinib-treated EGFR-positive patients defined with various cutpoints with Dako antibody varied between 8% and 12%, and with Zymed antibody between 10% and 13%. Lower cutoff points with Dako antibody provided the best discrimination between EGFR-positive and EGFR-negative patients for survival hazard ratios comparing gefitinib to placebo, with a significant treatment/cutoff point interaction for 10% cutoff point (P = .049). A similar but less apparent trend was noted for Zymed antibody, although the discrimination between hazard ratios was not significant for any cutoff point analyzed. CONCLUSIONS: Assessment with the Dako PharmDx kit and percentage of cells with positive staining may provide more accurate prediction of differential effect on survival with gefitinib than assessment with Zymed antibody and staining index. Using higher cutpoints to define positivity does not improve test discrimination.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subjectNon-Small-Cell Lung Canceren
dc.subjectClinical Trialen
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshImmunohistochemistry-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshPlacebos-
dc.subject.meshPredictive Value of Tests-
dc.subject.meshQuinazolines-
dc.subject.meshReceptor, Epidermal Growth Factor-
dc.subject.meshTumor Markers, Biological-
dc.titleEpidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentDivision of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA. Fred.Hirsch@UCHSC.eduen
dc.identifier.journalCanceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.